Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) EV-to-Revenue : 4.81 (As of Jun. 07, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Freeline Therapeutics Holdings's enterprise value is $2.99 Mil. Freeline Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.62 Mil. Therefore, Freeline Therapeutics Holdings's EV-to-Revenue for today is 4.81.

The historical rank and industry rank for Freeline Therapeutics Holdings's EV-to-Revenue or its related term are showing as below:

FRLN' s EV-to-Revenue Range Over the Past 10 Years
Min: -31.11 Med: -17.65 Max: -17.65
Current: -17.48

During the past 5 years, the highest EV-to-Revenue of Freeline Therapeutics Holdings was -17.65. The lowest was -31.11. And the median was -17.65.

FRLN's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.94 vs FRLN: -17.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-07), Freeline Therapeutics Holdings's stock price is $6.48. Freeline Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.14. Therefore, Freeline Therapeutics Holdings's PS Ratio for today is 45.31.

Freeline Therapeutics Holdings EV-to-Revenue Historical Data

The historical data trend for Freeline Therapeutics Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings EV-to-Revenue Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-Revenue	Get a 7-Day Free Trial													-	-	-	-31.03	-17.65

Competitive Comparison of Freeline Therapeutics Holdings's EV-to-Revenue

For the Biotechnology subindustry, Freeline Therapeutics Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Freeline Therapeutics Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's EV-to-Revenue falls into.

Freeline Therapeutics Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Freeline Therapeutics Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2.993	/	0.622
	=	4.81

Freeline Therapeutics Holdings's current Enterprise Value is $2.99 Mil.
Freeline Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.62 Mil.

Freeline Therapeutics Holdings (NAS:FRLN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Freeline Therapeutics Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	6.48	/	0.143
	=	45.31

Freeline Therapeutics Holdings's share price for today is $6.48.
Freeline Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.

Freeline Therapeutics Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.